Document Detail


Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia.
MedLine Citation:
PMID:  8638189     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Paclitaxel is a novel anticancer drug that is being increasingly used to treat cancer of the breast and other organs. We describe a patient with metastatic breast cancer and liver dysfunction who had severe mucocutaneous toxicity after administration of a standard dose of paclitaxel. Another interesting finding in this patient was that the administration of paclitaxel led to a prompt resolution of parathyroid hormone-related protein (PTHrP)-mediated hypercalcemia, which had previously proven to be refractory to multiple conventional antihypercalcemic agents as well as anthracycline-containing chemotherapy combination. The need for definitive guidelines for paclitaxel administration in the setting of hepatic dysfunction and the potentially unique sensitivity of PTHrP--producing cells to paclitaxel are discussed.
Authors:
J Y Payne; F Holmes; P R Cohen; R Gagel; A Buzdar; K Dhingra
Related Documents :
9435929 - Efficacy and safety of docetaxel in clinical trials.
7481869 - Carboplatin versus cisplatin in ovarian cancer.
14523789 - Oxaliplatin-safety profile: neurotoxicity.
11340899 - Docetaxel in prostate cancer.
11098349 - Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions.
2510769 - Phase i trial of mitomycin c immunoconjugates cocktails in human malignancies.
2982719 - Subclassification of small cell cancer of the lung: the southeastern cancer study group...
21414419 - Design and engineering of nanogels for cancer treatment.
7040539 - A second look at cimetidine.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Southern medical journal     Volume:  89     ISSN:  0038-4348     ISO Abbreviation:  South. Med. J.     Publication Date:  1996 May 
Date Detail:
Created Date:  1996-07-08     Completed Date:  1996-07-08     Revised Date:  2006-06-29    
Medline Journal Info:
Nlm Unique ID:  0404522     Medline TA:  South Med J     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  542-5     Citation Subset:  AIM; IM    
Affiliation:
Department of Breast and Gynecologic Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anthracyclines / administration & dosage
Antineoplastic Agents, Phytogenic / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms / drug therapy,  secondary
Drug Eruptions / etiology*
Erythema Multiforme / chemically induced*
Female
Humans
Hyperbilirubinemia / complications*
Hypercalcemia / drug therapy
Liver Neoplasms / drug therapy,  secondary
Middle Aged
Mouth Diseases / chemically induced
Neoplasm Proteins / antagonists & inhibitors
Paclitaxel / adverse effects*
Parathyroid Hormone / antagonists & inhibitors
Parathyroid Hormone-Related Protein
Proteins / antagonists & inhibitors
Vaginal Diseases / chemically induced
Chemical
Reg. No./Substance:
0/Anthracyclines; 0/Antineoplastic Agents, Phytogenic; 0/Neoplasm Proteins; 0/PTHLH protein, human; 0/Parathyroid Hormone; 0/Parathyroid Hormone-Related Protein; 0/Proteins; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Double-lumen esophagus: formation of a new lumen or septation of the existing one?
Next Document:  Laryngeal mask airway: uses in anesthesiology.